Zusammenfassung
Verhaltensstörungen, Depressionen, isolierte kognitive Störungen, pharmakotoxische Psychosen und schließlich dementive Veränderungen werden in zunehmendem Maße bei Parkinson-Patienten beobachtet und mÜssen bei der Behandlung berÜcksichtigt werden. Zur Zeit James Parkinsons stand die Beurteilung der motorischen StÖrung vÖllig im Vordergrund. HÖhere psychische Funktionen — mit Ausnahme von Depressionen, seltenen sensorischen Mißempfindungen und im Finalstadium auftretende delirante Zustandsbilder — wurden im wesentlichen bis zur EinfÜhrung der modernen Anti-Parkinson-Therapie selten und nur am Rande beschrieben. In den letzten hundert Jahren hat sich die durchschnittliche Lebenserwartung in den Industriestaaten nahezu verdoppelt, und es kam zu einer explosionsartigen Zuwachsrate der Hochbetagten von mehreren 100 bis über 1000% (Rückert 1984).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Agid Y, Javoy-Agid F, Ruberg M (1987) Biochemistry of neurotransmitters in Parkinson’s disease. In: Marsden CD, Fahn S (eds) Movement disorders 2. Butterworth, London, pp 166–230
Ambrozi L, Danielczyk W (1988) Die Behandlung zerebraler FunktionsstÖrungen mit Memantine bei psychogeriatrischen Patienten — Ergebnisse einer Phase-II-Doppelblindstudie. Pharmacopsychiatry 21: 144–146
Andersen J, Aabro E, Gulmann N, Hjelmisted A, Pedersen HE (1980) Anti-depressive treatment in Parkinson’s disease: a controlled trial of the effect of nortriptyline in patients with PD treated with L-dopa. Acta Neurol Scand 62: 210–219
Baldessarini RJ, Marsh E (1990) Fluoxetine and side effects [Letter]. Arch Gen Psychiatry 47: 191–192
Baldessarini RJ, Frankenburg FR (1991) Clozapine: a novel antipsychotic agent. N Engl J Med 324: 740–754
Baldwin RC, Benbow SM, Marriott A, Tomenson B (1993) Depression in old age. A reconsideration of cerebral disease in relation to outcome. Br J Psychiatry 163: 82–90
Barbeau A, Mars H, Gillo-Joffroy L (1971) Adverse clinical side effects of levo-dopa therapy. In: Mcdowell FH, Markham CH (eds) Recent advances in Parkinson’s disease. FA Davis, Philadelphia, pp 203–257
Barber J, Tomer R, Sroka H, Myslobodsky MS (1985) Does unilateral dopamine deficit contribute to depression? Psychiatr Res 15: 17–24
Beasley BL, Nutt JG, Davenport R W, Chase TN (1980) Treatment with tryptophan of levodopa-associated psychiatric disturbances. Arch Neurol 37: 155–156
Ben-Shlomo Y, Marmot MG (1994) Survival and cause of death in Parkinson’s disease: possible clues to aetiology. Clin Neuropharmacol VIII/1: 143
Birkmayer W, Riederer P (1980) Die Parkinson-Krankheit: Biochemie, Klinik, Therapie. Springer, Wien New York, S 167
Bonner D, Howard R (1995) Treatment-resistant depression in the elederly. Int Psychogeriatr 7 [Suppl]: 83–94
Booth G (1948) Psychodynamics in parkinsonism. Psychosom Med 10: 1–4
Bouchard RH, Pourcher E, Vincent P (1989) Fluoxetine and extrapyramidal side effects (Letters to the editor). Am J Psychiatry 146: 1352–1353
Braak H, Braak E, Yilmazer D, de Vos RAI, Jansen ENH, Bohl J (1996) Pattern of brain destruction in Parkinson’s and Alzheimer’s diseases. J Neural Transm 103: 455–490
Brannan T, Prikhojan A, Martínez-Tica J, Yahr MD (1995) In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism. J Neural Transm 10: 79–89
Braun R, Jahanshahi M (1995) Depression in Parkinson’s disease: a psychosocial viewpoint. Adv Neurol 65: 61–84
Brod TM (1989) Fluoxetine and extrapyramidal side effects (Letters to the editor). Am J Psychiatry 146: 1353
Brown GI (1975) Parkinsonism depression and ECT. Am J Psychiatry 132: 1084
Brown GL, Wilson WP (1972) Parkinsonism and depression. South Med J 65: 540–545
Brown RG, Maccarthy B, Gotham A-M, Der GJ, Marsden CD (1988) Depression and disability in Parkinson’s disease: a follow-up of 132 cases. Psychol Med 18: 49–55
Brücke T, Danielczyk W, Simayi M, Sofic E, Riederer P (1986) Terguride: partial dopamine agonist in the treatment of Parkinson’s disease. Adv Neurol 45: 573–576
Burke WJ, Peterson J, Rubin EH (1988) Electroconvulsive therapy in the treatment of combined depression and Parkinson’s disease. Psychosomatics 29: 341–346
Caley CF, Friedmann JH (1992) Does fluoxetine exacerbate Parkinson’s disease? J Clin Psychiatry 53: 278–282
Candy JM, Perry RH, Perry EK, Irving D, Blessed G, Fairbairn AF, Tomlinson BE (1983) Pathological changes in the nucleus of Meynert in Alzheimer’s disease and Parkinson’s disease. J Neurol Sci 54: 277–289
Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia — implications for schizophrenia and Parkinson’s disease. Trends Neurosci 13: 272–276
Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99: 47–53
Celesia GG, Barr AN (1970) Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 23: 193–200
Celesia CG, Wannamaker WM (1972) Psychiatric disturbances in Parkinson’s disease. Dis Nerv Syst 33: 577–583
Cooper JA, Sagar H, Doherty SM, Jordan N, Tidswell P, Sullivan EV (1992) Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. A follow-up study of untreated patients. Brain 115: 1701–1725
Cotzias GC, Papavasiliou PS, Gellene R (1969) Moditication of parkinsonism. Chronic treatment with 1-dopa. N Engl J Med 280: 337
Crow TJ, Johnstone EC, Mcclelland HA (1976) The coincidence of schizophrenia and parkinsonism: some neurochemical implications. Psychol Med 6: 227
Crystal H, Dickson D, Lizardi J, Davies P, Wolfson L (1990) Antemortem diagnosis of diffuse Lewy body disease. Neurology 40: 1523–1528
Damasio AR, Labo-Antunes J, Macedo C (1971) Psychiatric aspects in parkinsonism treated with 1-dopa. J Neurol Neurosurg Psychiatry 34: 502–507
Danielczyk W (1973) Die Behandlung von akinetischen Krisen. Med Welt 24 (NF): 1278–1282
Danielczyk W (1978) Akute psychische Störungen während der L-Dopa-Therapie von Parkinsonkranken. In: Fischer PA (Hrsg) Langzeitbehandlung des Parkinson-Syndroms. Schattauer, Stuttgart New York, S 211–218
Danielczyk W (1979) Akute pahrmakotoxische Psychosen bei chronischen zerebralen Erkrankungen. Wien Med Wochenschr 129[Suppl 55]: 3–15
Danielczyk W (1981) Die Behandlung von phar-makotoxischen Psychosen bei Parkinson-Patienten mit Clopenthixol. Wien Klin Wochenschr 93: 500–501
Danielczyk W (1983) Various mental behavioural disorders in Parkinson’s disease, primary degenerative senile dementia, and multi infarction dementia. J Neural Transm 56: 161–176
Danielczyk W (1986) Akinetische Krisen, akinetische Endzustände und Sterbealter bei hospitalisierten Parkinson-Patienten. In: Fischer PA (Hrsg) Spätsyndrome der Parkinson-Krankheit. Editiones Roche, Basel, S 89–98
Danielczyk W, Fischer P (1989) Parkinson’s disease: development of dementia in aging. In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy in Parkinson’s disease. Springer, Wien New York, pp 9–17
Danielczyk W, Fischer P (1990a) Psychiatric complications and shift of death age in Parkinson’s disease. Adv Neurol 53: 405–410
Danielczyk W, Fischer P (1990b) Neuroleptische Therapie bei Morbus Parkinson. In: Müller-Oerlinghausen B, Möller H-J, Rüther E (Hrsg) Thioxanthene in der neuroleptischen Behandlung. Springer, Berlin Heidelberg New York Tokyo, S 137–142
Danielczyk W, Fischer P, Laussegger C (1988) Antiparkinson-Therapie und Psychopharmaka. AuslÖsung von Psychosen durch Dosissteigerungen und medikamentÖse Wechselwirkungen. In: Fischer PA (Hrsg) Modifizierende Faktoren bei der Parkinson-Therapie. Editiones Roche, Basel, S 187–200
Danielczyk W, Simanyi M, Fischer P, Streifler M, Jellinger K (1989) Der differentialdiagnostische Wert des EEG im Verlauf von SDAT, MID und schwerer Depression im Alter. Forum Medizin, Gerontopsychiatrie: 245–264
Desmet Y, Ruberg M, Serdau M, Dubois B, Lhermitte F, Agid Y (1982) Confusion, dementia and anticholinergics in Parkinson’s disease. J Neurol Neurosurg Psychiatry 45: 1161–1164
Dingemanse J (1993) An update of recent moclobemide interaction data. Int Clin Psychopharmacol 7: 167–180
Doonief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R (1992) An estimate of the incidence of depression in idiopathic Parkinson’s disease. Arch Neurol 49: 305–307
Douyon R, Serby M, Klutchko B, Rotrosen J (1989) ECT and Parkinson’s disease revisited: a „naturalistic“ study. Am J Psychiatry 146: 1451–1455
Dovenmuehle R H, Verwoerdt A (1963) Physical illness and depressive symptomatology. II. Factors of length and severity of illness and frequency of hospitalization. J Am Geriatr Soc 18: 260
Dray A (1981) Serotonin in the basal ganglia: functions and interactions with other neuronal pathways. J Physiol Paris 77: 393–403
Dubois B, Ruberg M, Javoy-Agid F, Ploska A, Agid Y (1983) A subcortical-cortical cholinergic system is affected in Parkinson’s disease. Brain Res 288: 213–218
Dubois B, Danze F, Pillon B, Cusimano G, Lhermitte F, Agid Y (1987) Cholinergic-dependent cognitive deficits in Parkinson’s disease. Ann Neurol 22: 26–30
Dubois B, Defontaines B, Deweer B, Malapani C, Pillon B (1995) Cognitive and behavioral changes in patients with focal lesions of the basal ganglia. Adv Neurol 65: 29–41
Ebmeier K, Calder S, Crawford J, Stewart L, Besson J, Mutch W (1990) Clinical features predicting dementia in idiopathic Parkinson’s disease: a follow-up study. Neurology 40: 1222–1224
Factor SA, Singer C (1992) Neuroleptic malignant syndrome. In: Lang AE, Weiner WJ (eds) Drug-induced movement disorders. Futura, Mount Kisco, pp 199–230
Factor SA, Brown D, Molho ES, Podskalny GD (1994) Clozapine: a two year open trial in Parkinson’s disease patients with psychosis. Neurology 44: 544–546
Factor SA, Molho ES, Podskalny GD, Brown D (1995) Parkinson’s disease: drug-induced psychiatric states. Adv Neurol 65: 115–138
Fahn S, Snider S, Prasad ALN, Lane E, Makadon H (1975) Normalization of brain serotonin by L-tryptophan in levodopa treated rats. Neurology 25: 861–865
Fall P-A, Ekman R, Granérus A-K, Thorell L-H, Wålinder J (1995) ECT in Parkinson’s disease. Changes in motor symptoms, monoamine metabolites and neuropeptides. J Neural Transm 10: 129–140
Fibiger HC (1984) The neurogiological substrates of depression in Parkinson’s disease: a hypothesis. Can J Neurol Sci 11: 105–107
Fischer PA (1996) Lehrbuch der Gerontopsychiatrie — praktische Gerontopsychiatrie. Enke, Stuttgart
Fischer PA, Schneider E, Jacobi P (1982) Depressive Verstimmungen bei Parkinson-Kranken im Langzeitverlauf. In: Fischer PA (Hrsg) Psychopathologie des Parkinson-Syndroms. Editiones Roche, Basel, S 139–152
Fischer P, Danielczyes W, Simanyi M, Streifler MB (1990) Dopaminergic psychosis in advanced Parkinson’s disease. Adv Neurol 53: 391–397
Förstl H, Besthorn C, Sattel H, Zerfass R, Geiger-Kabisch C Schreiter-Gasser, Hentschel F (1996) Volumetrische Himveränderugen und quantitatives EKG bei normalem Altern und Alzheimer-Demenz. Der Nervenarzt 67: 53–61
Fras I, Litin EM (1968) Mental symptoms as an aid in the early diagnosis of carcinoma of the pancreas. Gastroenterology 55: 191–198
Frazer A Mendels J (1977) Use of 1-dope in depression. Adv Biochem Psychopharmacol 16: 671–675
Friedman JH (1991) The management of the levodopa psychoses. Clin Neuropharmacol 14: 283–295
Friedman J H, Lannon MC (1989) Clozapine in the treatment of psychosis in Parkinson’s disease. Neurology 39: 1219–1221
Fünfgeld EW (1972) Zweijährige Erfahrungen mit der Amantadintherapie bei Parkinsonismus. Ther Woche 39: 3282–3299
Fünfgeld EW (1995) Computerised brain electrical activity findings of Parkinson patients suffering from hyperkinetic side effects (hypersensitive dopamine syndrome) and a review of possible sources. J Neural Transm [Suppl 46]: 347–361
Fünfgeld KW, Zwischenbrugger H (1994) Hinweise auf eine cerebro-toxische Wirkung von hohen Dopa-Dosen bei der Parkinson-Krankheit. In: Huffmann G, Braune HJ, Henn KH (Hrsg) Extrapyramidalmotorische Erkrankungen. Einhorn Presse Verlag, S 344–349
Garcia C, Reding M, Blass J (1981) Overdiagnosis of dementia. J Am Geriatr Soc 29: 407–410
Gerlach J, Ahlfors UG, Amthor KF, Dencker SJ, Gravem A (1986) Effect of different neuroleptics in tardive dyskinesia and parkinsonism. Psychopharmacology 90: 423–429
Goldstein M, Lew JY, Hata F, Lieberman A (1978) Binding interactions of ergot alkaloids with monoaminergic receptors in the brain. Gerontology 25[Suppl I]: 76–85
Goodwin FK (1971a) Behavioral effects of 1-dopa in man. Sem Psychiatry 3: 477–492
Goodwin FK (1971b) Psychiatric side effects of levodopa in man. JAMA 218: 1915–1920
Gotham AM, Brown R G, Marsden CD (1988) Depression in Parkinson’s disease: a qualitative and quantitative analysis. J Neurol Neurosurg Psychiatry 49: 381–389
Götz ME, Fischer P, Gsell W, Riederer P, Streifler M, Simanyi M, Müller F, Danielczyk W (1995) Platelet monoamine oxidase B activity in dementia: a 4 year follow-up. J Neural Transm [Gen Sect] 102: XVII
Granérus AK, Axelsson O, Fall P A, Fredriksson M, Hansson G, Lindvale B, Olsson JE (1994) High age at onset indication of low risk for Parkinson’s disease? Clin Neuropharmacol VIII/1: 119–120
Greene P, Cote L, Fahn S (1993) Treatment of drug-induced psychosis in Parkinson’s disease with clozapine. Adv Neurol 60: 703–706
Growdon JH, Corkin S, Rosen TJ (1990) Distinctive aspects of cognitive dysfunction in Parkinson’s disease. Adv Neurol 53: 365–376
Heinrich K, Tegeler J (1983) Dyskognitive, apathische und extrapyramidale Syndrome bei Langzeit-Neurolepsie. In: Hippius H, Klein HE (Hrsg) Therapie mit Neuroleptika. Perimed, Erlangen
Herrschaft H (1992) Piracetam. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka, Bd 5. Parkinsonmittel und Nootropika. Springer, Wien New York, S 189–200
Hershey L, Feldman B, Kim K, Commichau C, Lichter D (1991) Tremor at onset. Arch Neurol 48: 1049–1051
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442
Hofman A, Shulte W, Tanja T, van Duijn CM, Haaxma R, Lameris AJ, Otten VM, Saan RJ (1989) History of dementia and Parkinson’s disease in 1 st-degree relatives of patients with Alzheimer disease. Neurology 39: 1589–1592
Hubble JP, Koller WC (1995) The Parkinsonian personality. Adv Neurol 65: 43–48
Huber SJ, Freidenberg DL, Shuttleworth EC, Paulson GW, Clapp LE (1989) Neuropsychological similarities in lateralized parkinsonism. Cortex 25: 461–470
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181–184
Iverson S (1984) Cortical monoamines and behavior. In: Descarries L, Reader LA, Jasper HH (eds) Monoamine innervation of the cerebral cortex. Alan Liss, New York, p 349
Jackson JA, Free GBM, Pike HV (1923) The psychic manifestations in paralysis agitans. Arch Neurol Psychiatry 10: 680–684
Jellinger KA, Bancher CH (1995) Structural basis of mental impairment in Parkinson’s disease. Neuropsychiatrie 9/1: 9–13
Jenkins RB, Groh RH (1970) Mental symptoms in parkinsonian patients with L-dopa. Lancet ii: 177–180
Joborn C, Hetta J, Palmer M, Akerström G, Ljunghall S (1986) Psychiatric symptomatology in patients with primary hyperparathyroidism. Up J Med Sci 91: 77–87
Jouvent R, Abensour P, Bonnet AM, Widlocher D, Agid Y, Lhermitte F (1983) Antiparkinsonian and anti-depressant effects of high doses of bromocriptine: an independent comparison. J Affect Disord 5: 141–145
Keyser DL, Rodnitzky RL (1991) Neuroleptic malignant syndrome in Parkinson’s dease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med 151: 794–796
Klawans HL, Goetz CG, Nausieda PA, Weiner WJ (1977) Levodopa-induced dopamine receptor hypersensitivity. Ann Neurol 2: 125–129
Koller W (1984) Disturbances of recent memory function in parkinsonian patients on anticholinergic therapy. Cortex 20: 307–311
Kornhuber J, Weller M (1994) Neuroleptic malignant syndrome. Curr Opin Neurol 7: 353–357
Kornhuber J, Weller M, Riederer P (1993) Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic Parkinsonian crisis. J Neural Transm 6: 63–72
Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer W (1995) Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 34/7: 713–721
Korsgaard S, Noring U, Povlsen UJ, Gerlach J (1986) Effects of Citalopram, a specific serotonin uptake inhibitor, in tardive dyskinesia and parkinsonism. Clin Neuropharmacol 9: 52–57
Kostic VS, Filipovic SR, Lesic D, Momcilovic D, Sokic D, Sternic N (1994) Effect of age at onset on frequency of depression in Parkinson’s disease. J Neurol Neurosurg Psychiatry 57: 1265–1267
Kurlan R, Dimitsopulos T (1992) Selegiline and manic behavior in Parkinson’s disease. Arch Neurol 49: 1231
Kurland L (1958) Epidemiology: incidence, geographic distribution and genetic considerations. In: Field W (ed) Pathogenesis and treatment of parkinsonism. Charles C Thomas, Springfield, pp 5–43
Laitinen L (1969) Desipramine in the treatment of Parkinson’s disease. Acta Neurol Scand 45: 109–113
Lange KW (1999) Cognitive functions in Parkinson’s disease. J Neural Transm 106/1: XXI
Leonard BE (1993) The comparative pharmacology of new antidepressants. J Clin Psychiatry 54: 3–15
Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE (1979) Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29: 1253–1260
Levin BE, Katzen HL (1995) Early cognitive changes and nondementing behavioral abnormalities in Parkinson’s disease. Adv Neurol 65: 85–95
Levin BE, Llabre MM, Reisman S (1991) A retrospective analysis of the effects of anticholinergic medication on memory performance in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 3: 412–416
Mahieux F, Fénelon G, Flahault A, Manifacier MJ, Michelet D, Boller F (1998) Neuropsychological prediction of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 64: 178–183
Marder K, Flood P, Cote L, Mayeux R (1990) A pilot study of risk factors for dementia in Parkinson’s disease. Mov Disord 5: 156–161
Marsh CG, Markham CH (1973) Does levodopa alter depression and psychopathology in parkinsonism patients? J Neurol Neurosurg Psychiatry 36: 925–935
Maritila RJ, Kuopio AM, Rinne UK (1994) Survival in Parkinson’s disease: early levodopa treatment enhances life expectancy. Clin Neuropharmacol VIII/1: 120–121
Mayberg HS, Solomon DH (1995) Depression in Parkinson’s disease: a biochemical and organic viewpoint. Adv Neurol 65: 49–60
Mayberg HS, Starkstein SE, Sadzot IB, Preziosi T, Andrezejewski PL, Dannals RF, Wagner HN Jr, Robinson RG (1990) Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol 28: 57–64
Mayeux R, Stern Y, Rosen J, Leventhal J (1981) Depression, intellectual impairment, and Parkinson disease. Neurology 31: 645–650
Mayeux R, Stern Y, Cote L, Williams JBW (1984) Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology 34: 642–646
Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, Stern Y (1992) A population-based investigation of Parkinson’s disease with and without dementia. Arch Neurol 49: 492–497
Mccance-Katz EF, Marek KL, Price LH (1992) Serotonergic dysfunction in depression associated with Parkinson’s disease. Neurology 42: 1813–1814
Melamed E, Zoldan J, Friedberg G, Goldberg-Stein H (1993) Is hallucinosis in Parkinson’s disease due to central serotonergic hyperactivity? Mov Disord 8: 406–407
Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC (1979) Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 45: 165–175
Mendlewicz J, Yahr F, Yahr MD (1976) Psychiatric disorders in Parkinson’s disease treated with 1-dopa: a genetic study. Editiones Roche, Basel, p 103 (Adv Parkinsonism)
Menza MA, Golbe LI, Codi RA, Forman NE (1993) Dopamine-related personality traits in Parkinson’s disease. Neurology 43: 505–508
Mindham RHS (1970) Psychiatric symptoms in parkinsonism. J Neurol Neurosurg Psychiatry 33: 188–191
Mitscherlich M (i960) The psychic state of patients suffering from parkinsonism. Karger, Basel, pp 317–324 (Adv Psychosom Med)
Mortimer JA, Christensen KJ, Webster DD (1985) Parkinsonian dementia. In: Frederiks JAM (ed) Handbook of clinical neurology 2 (46): neurobehavioral disorders. Elsevier, New York, pp 371–384
Muller SR, Dastoor DP, Klinger A, Boillat J (1979) Amantadine in senile dementia: electroencephalographic and clinical effects. J Am Geriatr Soc 27: 9–16
Mundinger F, Wünsch F (1980) 7-Jahres-Langzeitergebnisse der stereotaktischen Tremorbehandlung beim Parkinson-Syndrom. In: Fischer PA (Hrsg) Parkinson-Syndrom: Kombinations-und Begleittherapien. Fischer, Stuttgart New York, S 199–209
Naber D, Leppig M, Grohmann R, Hippius H (1989) Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia — a retrospective study of 387 patients. Psychopharmacology 99: 73–76
Nahmias C, Garnett ES, Firnau G, Lang A (1985) Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 69: 223–230
Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL (1982) Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 5: 183–194
Ng LKY, Chase TN, Colburn RW, Kopin IJ (1972) Release of 3H-dopamine by L-5-hydroxytryptophan. Brain Res 45: 499–505
Nies A, Robinson DS, Friedman MJ, Green R, Cooper TB, Ravaris CL, Ives JO (1977) Relationship between age and tricyclic antidepressant plasma levels. Am J Psychiatry 134: 790–793
Olichneyj M, Douglas G, Corey-Bloom J, Thal LJ (1995) The spectrum of diseases with diffuse lewy bodies. Adv Neurol 65: 159–170
Paulus W, Jellinger K (1991) The neurpathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 50: 743–755
Peuch A (1993) Contributions of pharmacology in the treatment of resistance to antidepressive agents. Encephale 19: 407–412
Pillhatsch K (1995) Korrelation des organischen Psychosyndroms im Alter mit apparativen Befunden — Aussagekraft von EKG und CCT bei psychiatrischen Erkrankungen im Alter. 2 Gerontol 18: 330–336
Poewe W, Karamat E, Kemmler G W, Gerstenbrand F (1990) The premorbid personality of patients with Parkinson’s disease: a comparative study with healthy controls and patients with essential tremor. Adv Neurol 53: 339–342
Post F (1962) The significance of affective symptoms in old age [Maudsley Monograph 10]. Oxford University Press, London
Prick JJG (1966) Genuine parkinsonism. A psychosomatic, anthropological-psychiatric approach. Abs Work Congress of Psychiatry Madrid, Sandorama Special Number IV
Rajput A, Offord K, Beard C, Kurland L (1984) Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 16: 278–283
Rajput AH, Uitti RJ, Ho M, Offord K, Rajput A, Basran P (1994) Current survival profile in parkinsonism. Clin Neuropharmacol VIII/1: 121–122
Riederer P, Lange KW, Kornhuber J, Danielczyk W (1992) Glutamatergic-dopaminergic balance in the brain. Arzneimittelforschung/Drug Res 42(I), 2a: 265–268
Robins AH (1986) Depression in patients with parkinsonism. Br J Psychiatry 128: 141–145
Ruggieri S, Fabbrini G, Bramante L, DePandis, Stocchi, Barbanti P, Vacca L, Manfredi M (1996) An open study with reversible MAO-A inhibitors in complicated Parkinson’s disease. Adv Neurol 69: 595–598
Russ M, Fischer PA (1994) Sind die kognitiven Störungen des Parkinson-Kranken „dopaminerg“? In: Fischer PA (Hrsg) Parkinson-Krankheit, Bedeutung nichtdopaminerger FunktionsstÖrungen. Editiones Roche, Basel, S 133–153
Rückert W (1984) BevÖlkerungsentwicklung und Altenhilfe von der Kaiserzeit bis zum Jahre 2000. Kuratorium Deutsche Altenhilfe, KÖln, S 98
Sadah M, Braham J, Madan M (1982) Effects of anticholinergic drugs on memory in Parkinson’s disease. Arch Neurol 39: 666–667
Santamaria J, Tolosa E, Valles A (1986) Parkinson’s disease with depression: a possible subgroup of idipathic parkinsonism. Neurology 36: 1130–1133
Schneider E (1999) Therapy of depression and pharmacotoxic psychosis. J Neural Transm 106/1: XXX
Schneider E, Fischer PA, Jacobi P, Grotz A (1984) Exogene Psychosen beim Parkinson-Syndrom. Häufigkeit und Entstehungsbedingungen. Fortschr Neurol Psychiat 52: 207–214
Schoenberg B, Anderson D, Haerer A (1985) Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology 35: 841–845
Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatr Neurol Sci 235: 60–64
Schwab RS, Fabing HD, Prichard JS (1950) Psychiatric symptoms and syndromes in Parkinson’s disease. Am J Psychiatry 107: 901–907
Schwab RS, England AC Jr, Poskaner DC (1969) Amantadine in the treatment of Parkinson’s disease. J Am Med Assoc 208: 1168–1170
Siemers ER, Schekhar A, Quaid K, Dickson H (1993) Anxiety and motor performance in Parkinson’s disease. Mov Disord 8: 501–506
Spicer KB, Roberts RJ, Le Witt PA (1988) Neuropsychological performance in lateralized parkinsonism. Arch Neurol 45: 429–432
Starkstein SE, Berthier ML, Bolduc PL, Preziosi TJ, Robinson RG (1989a) Depression in patients with early versus later onset of Parkinson’s disease. Neurology 39: 1141–1145
Starkstein SE, Robinson RG, Honig MA, Parikh RM, Joselyn J, Price TR (1989b) Mood changes after right hemisphere lesions. Br J Psychiatry 155: 79–85
Starkstein SE, Bolduc PL, Mayberg HS, Preziosi TJ, Robinson RG (1990a) Cognitive impairments and depression in Parkinson’s disease: a follow-up study. J Neurol Neurosurg Psychiatry 53: 597–602
Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG (1990b) Depression in Parkinson’s disease. J Nerv Ment Dis 178: 21–31
Starkstein SE, Mayberg HS, Preziosi TJ, Anrezejewski P, Leiguarda R, Robinson RG (1992) Reliability, validity, and clinical correlates of apathy in Parkinson’s diseases. J Neuropsychiat Clin Neurosci 4: 134–139
Stenager EN, Wermuth L, Stenager E, Boldsen J (1994) Suicide in patients with Parkinson’s disease. An epidemiological study. Acta Psychiatr Scand 90: 70–72
Strang RR (1965) Imipramine in the treatment of parkinsonism: a double-blind placebo study. Br J Med 2: 33–34
Strauss WH, Klieser E, Luethke H, Burtscheidt W (1988) Dyscognitive syndrome in neuroleptic therapy. Pharmacopsychiatry 21: 298–299
Streifler M, Hait Z (1973) Amantadinderivate bei Parkinsonismus im Blindversuch. Ther Woche 40: 3549–3652
Suchowersky O, Devries J (1990) Possible interaction between deprenyl and prozac [Letter]. Can J Neurol Sci 17: 352–353
Swanson PD (1994) Drug treatment of Parkinson’s disease: is „polytherapy“ best? J Neurol Neurosurg Psychiatry 57: 401–403
Tate JL (1989) Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 146: 399–400
Tatemichi TK, Sacktor N, Mayeux R (1994) Dementia associated with cerebrovascular disease, other degenerative disease, and metabolic disorders. In: Terry RD, Katzmann R, Slick KL (eds) Alzheimer disease. Raven Press, New York, pp 123–166
Tiffany T, Cummings JL (1998) Depression in Parkinson’s disease. Pharmacological characteristics and treatment. Drugs & Aging 12: 55–74
Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B (1989) Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12: 375–383
Uitti R J, Rajput AH, Ahlskog JE, Offord KP, Ho MM, Prasad M, Rajput A, Basran P (1993) Amantadine treatment is an independent predictor of improved survival in parkinsonism. Can J Neurol Sci 20[Suppl 4]: 235
van Tol HHM, Bunzow JR, Guan H-C et al. (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614
Venkateswarlu T, Staley CJ, Neal CD (1990) Zuclopenthixol dihydrochloride in the management of behavioural disorders in elderly demented patients: a dose-ranging study. Int J Geriatr Psychiatry 5: 265–270
Vogel HP (1982) Symptoms of depression in Parkinson’s disease. Pharmacopsychiatry 15: 192–196
Warborton JW (1967) Depressive symptoms in Parkinson patients referred for thalamotomy. J Neurol Neurosurg Psychiatry 30: 368–370
Wolters ECH, Hurwitz TA, Peppard RF, Calne DB (1989) Clozapine: an antipsychotic agent for Parkinson’s disease? Clin Neuropharmacol 12: 83–90
Wong DT, Bymaster FP, Reid LR, et al. (1983) Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol 32: 1287
Yahr MD, Duvoisin RC, Scheer MJ, Barrett RE, Hoehn MM (1969) Treatment of parkinsonism with levodopa. Arch Neurol (Chic) 21: 343–354
Yaryura-Tobias JA, Diamond B, Merlis S (1970) Psychiatric manifestations of levodopa. Dis Nerv Syst 31: 60–63
Young RC, Alexopoulos GS, Shamoian CA (1985) Dissociation of motor response from mood and cognition in a parkinsonian patient treated with ECT. Biol Psychiatry 20: 566–569
Yudofsky SC (1979) Parkinson’s disease, depression, and electroconvulsive therapy: a clinical and neurobiologie synthesis. Compr Psychiatry 20: 579–581
Zetusky W, Jankovic J, Pirozzolo F (1985) The heterogeneity of Parkinson’s disease: clinical and prognostic implications. Neurology 35: 1222–1224
Zoldan J, Friedberg G, Weizman A, Melamed E (1996) Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-Dopa therapy in advanced Parkinson’s disease. Adv Neurol 69: 541–544
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Wien
About this chapter
Cite this chapter
Danielczyk, W. (1999). Exkurs: Begleitende Behandlung von psychiatrischen Symptomen bei Morbus Parkinson. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6400-6_34
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6400-6_34
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-7315-2
Online ISBN: 978-3-7091-6400-6
eBook Packages: Springer Book Archive